Related Experiment Video
Updated: May 27, 2026
08:34
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Probiotics for patients with hepatic encephalopathy
Richard G McGee1, Anouk Bakens, Kerrie Wiley
1Sydney School of Public Health, University of Sydney, Sydney, Australia. dr.richardmcgee@gmail.com
The Cochrane Database of Systematic Reviews
|November 11, 2011
Summary
Probiotics may lower ammonia levels in hepatic encephalopathy patients but do not significantly improve other outcomes. More research is needed to confirm probiotic efficacy for this liver condition.
Area of Science:
- Gastroenterology and Hepatology
- Microbiology and Immunology
- Clinical Trials and Evidence-Based Medicine
Background:
- Hepatic encephalopathy (HE) is a severe brain dysfunction linked to liver failure or portosystemic shunts.
- Both overt and minimal HE significantly impair patients' quality of life and increase healthcare burdens.
- Probiotics, live microorganisms, are investigated for potential health benefits.
Purpose of the Study:
- To evaluate the efficacy and safety of probiotics in treating acute or chronic hepatic encephalopathy.
- To compare probiotics against placebo, no intervention, or other treatments using randomized controlled trials.
Main Methods:
- Systematic literature search across multiple databases (Cochrane, MEDLINE, EMBASE, etc.) up to April 2011.
- Inclusion of randomized trials comparing probiotics with placebo, no intervention, or other therapies for HE.
- Meta-analysis using random-effects models due to heterogeneity; assessment of risk of bias.
Main Results:
- Seven trials with 550 participants were analyzed; all trials had a high risk of bias.
- Probiotics showed no significant difference in mortality, recovery, adverse events, or quality of life compared to placebo.
- A significant reduction in plasma ammonia was observed at one and three months with probiotic use versus placebo.
Conclusions:
- Current evidence is limited by high risk of bias and small sample sizes in included trials.
- While probiotics may reduce plasma ammonia, their efficacy in improving clinically relevant HE outcomes remains unproven.
- Further high-quality randomized clinical trials are necessary to establish the role of probiotics in HE management.
Related Concept Videos
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:22Probiotics
Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...